IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and…
Month: November 2017
LabBag Automates Preparation, Management of Stem Cells
Stem cells are a way to test new drugs and therapies that would otherwise require the use of animals or difficult to obtain patient samples. While they have great potential for medicine, stem cells are hard to manage, particularly growing and differentiating them into other cells, and then storing them for later use. Now a […]
Orion cortical visual prosthesis system gets FDA expedited access pathway designation
The FDA has granted expedited access pathway designation to Second Sight Medical Products for its Orion cortical visual prosthesis system, according to a company press release.
The designation, given to select medical devices, is intended to help patients have more timely access to devices by expediting their development, assessment and review, the release said.
“These advantages potentially allow the FDA to approve Orion with fewer patients and with a shorter follow-up timeline, thus facilitating a faster entry of Orion into the commercial market,” Will McGuire, president and CEO
New Brain Probe Maps Dopamine in Brain to Help Study Psychiatric Drugs and Diseases
Researchers at University of California, Berkeley have developed special sensors that provide a look at the location and concentration of neurotransmitter chemicals, such as dopamine, inside living brain tissue. The new capability should help scientists to study a variety of neurological conditions and the drugs that are used to treat them. The nano-scale sensors are made […]
DynamX, a Novel Stent That Turns from Rigid to Flexible While Inside Vessel
With every heart beat, our blood vessels expand and contract, something known as pulsatile motion. When commonly used metal stents are placed within vessels, they prevent those vessels from exhibiting pulsatile motion. This may be a cause of or a compounding factor for restenosis and may even lead to a cardiovascular disease to develop faster. […]
Iridex posts $3.1 million quarterly loss
Iridex reported a net loss of $3.1 million, or $0.27 per share, in the third quarter of 2017 compared with a net loss of $0.7 million, or $0.07 per share, in the same time period of 2016, according to a press release.
Revenue grew by 11% from $9.8 million in 2016’s third quarter to $10.9 million.
Operating expenses increased from $5.5 million in the third quarter of 2016 to $7.4 million in the third quarter of 2017, while a loss from operations rose from $1.2 million to $3.1 million.
The company reported cash and cash equivalents of $22.8 million as of Sept. 30.
The Lions Eye Institute for Transplant & Research Launches One World Sight Alliance to Help Eradicate Preventable Blindness Throughout the World
TAMPA, Fla.–(BUSINESS WIRE)–#blindness–The Lions Eye Institute for Transplant & Research launches One World Sight Alliance to help eradicate preventable blindness throughout the world.
An Ingredient Technology Company Powering the World of Wearables: Interview with Valencell VP Ryan Kraudel
At Medgadget, we cover a lot of digital health devices and wearables. Some are developed by startups, while others come from brand name businesses that have branched out into this new and growing market. A common thread among most of the digital health technologies covered is the need to record data through various sensor technologies. However, […]
A Clear View for Hunting Season with Fog Zero
PENSACOLA, Fla.–(BUSINESS WIRE)–#fog–With seasons changing and temperature dropping across the country, hunting season is nearly in full swing. For many, hunting season is about making memories and enjoying time doing something they love. Experience…
iVeena Delivery Systems Completes Phase 1/2a Pilot Clinical Study of IVMED-10 for Post-Cataract Inflammation
SALT LAKE CITY–(BUSINESS WIRE)–iVeena completes initial safety clinical study of IVMED-10, a therapy that treats front and back of the eye inflammation after cataract surgery
EMS-GRIVORY to Introduce Green Partnership with API at Hong Kong Optical Fair
MUSSOLENTE, Italy–(BUSINESS WIRE)–$TSE #Trinseo–API, a Trinseo company, announces partnership with EMS-GRIVORY to develop a series of sustainable eyewear solutions with a lower environmental impact
Ophthalmic Industry Leader William J. Link, Ph.D., Joins LENSAR, Inc. Board of Directors as Chairman
ORLANDO, Fla.–(BUSINESS WIRE)–William J. Link, Ph.D. joins LENSAR, Inc. board of directors as chairman.
What you need to know about esotropia
A look at esotropia, a condition that causes the eyes to turn inward. Included is detail on the common causes and how the condition is diagnosed.
Second Sight Receives FDA Expedited Access Pathway Designation for the Orion Cortical Visual Prosthesis System
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Expedited Access Pathway designation for the Orion™ Cortical Visual Prosthesis System (Orion). This designation is given to a few select medical dev
Visioneering Technologies Promotes Jeff Babbe to District Manager for the Midwest Region
ATLANTA–(BUSINESS WIRE)–Highlighting their commitment to promoting top performers, Visioneering Technologies promotes Jeff Babbe to District Manager for Midwest
Ophthotech Reports Third Quarter 2017 Financial and Operating Results
NEW YORK–(BUSINESS WIRE)–Ophthotech today announced financial and operating results for the third quarter ended September 30, 2017 and provided a business update.
iVeena Delivery Systems Receives FDA Orphan Drug Designation for IVMED-80 for the Treatment of Keratoconus
SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems is awarded orphan drug designation for IVMED-80, a novel eye-drop therapy treating keratoconus
Reminder: Medgadget Sci-Fi Writing Contest!
We are excited to announce the return of the Medgadget Sci-Fi Writing Contest! We cover the latest medical technologies on a daily basis, many of which may seem like they come from the future. Yet, we feel that the medical device industry can benefit from the work of creative fiction writers, as literature of the […]
Specific gene variants play role in response to anti-VEGF treatment
Specific genetic variants were found to play a role in the response to anti-VEGF treatment for age-related macular degeneration in a real-life retrospective study conducted in six Spanish tertiary care hospitals.The study included 403 eyes of 403 conse…
Glaukos Corporation Announces Third Quarter 2017 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …